Figure 7.

Inhibition of BLT2 significantly reduced tumour progression in an orthotopic breast tumour model. (A) Representative photographs of tumour extracted from the mice treated with or without paclitaxel (15 mg kg⁻¹, i.p., once a week for 4 weeks) and LY255283 (2.5 mg kg⁻¹, i.p., twice a week for 4 weeks). (B) Breast tumour weight was determined in mice administrated LY255283 or DMSO along with paclitaxel (N=6 per group). Data are presented as scatter dot plot and line indicate mean. Data are means±s.d. of values from six mice of each group. ‡P<0.005. (C) A proposed scheme for the involvement of the BLT2 cascade in paclitaxel resistance of breast cancer cells. LTB₄–BLT2 pathway activation induces ERK activation. Then, ERK activation regulates MDR1 protein stability, which leads to paclitaxel resistance.